In Brief: EP MedSystems
This article was originally published in The Gray Sheet
EP MedSystems: Clinical trials for the firm's Alert catheter system for internal cardioversion of atrial fibrillation began the week of Dec. 8 at Duke University Medical Center, the company says. The Alert catheter delivers low energy electrical impulses to the interior of the heart in order to convert AF to a normal heart rhythm. Two additional centers, the Medical Center of the University of Alabama Birmingham and Allegheny University of the Health Sciences, will soon be added to the study...
You may also be interested in...
The pharma giants are joining forces to help the UK reach its ambitious target of testing 100,000 people a day for coronavirus by the end of April.
Angelini is looking to take its recently-acquired ThermaCare brand to the next level by establishing a direct base in Germany to market the product and through a new distribution deal with Norway's Navamedic.
BD and BioMedomics have released a new rapid point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19.